<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900704</url>
  </required_header>
  <id_info>
    <org_study_id>SPC-SER120-DB4-201301</org_study_id>
    <nct_id>NCT01900704</nct_id>
  </id_info>
  <brief_title>Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4</brief_title>
  <acronym>DB4</acronym>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serenity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Serenity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of SER120 nasal spray formulations in patients with&#xD;
      nocturia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With Equal of Greater Than 50% Reduction in Mean Nocturic Episodes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of participants with equal of greater than 50% reduction in mean nocturic episodes over the twelve week period</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">810</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>SER120 750 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 750 ng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SER120 1500 ng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SER120 1500 ng</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 750 ng</intervention_name>
    <description>SER120 750 ng</description>
    <arm_group_label>SER120 750 ng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SER120 1500 ng</intervention_name>
    <description>SER120 1500 ng</description>
    <arm_group_label>SER120 1500 ng</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female 50 years or older&#xD;
&#xD;
          -  Nocturia of 6 or more months duration averaging greater than 2 nocturic episodes per&#xD;
             night&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHF&#xD;
&#xD;
          -  Diabetis Insipidus&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Incontinence&#xD;
&#xD;
          -  Illnesses requiring systemic steroids&#xD;
&#xD;
          -  Malignancy within the past 5 years&#xD;
&#xD;
          -  Sleep apnea&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Unexplained pelvic mass&#xD;
&#xD;
          -  Urinary bladder neurological dysfunction&#xD;
&#xD;
          -  Urinary bladder surgery or radiotherapy&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stephen M. Auerbach, MD</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>July 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2013</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>November 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2020</results_first_posted>
  <disposition_first_submitted>November 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 24, 2015</disposition_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SER120 1500 ng</title>
          <description>All participants received SER120 1500 ng once daily</description>
        </group>
        <group group_id="P2">
          <title>SER120 750 ng</title>
          <description>All participant received SER120 750 ng once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>All participants received Placebo once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="270"/>
                <participants group_id="P3" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="235"/>
                <participants group_id="P3" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-To-Treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>SER120 750 ng</title>
          <description>All participants received SER120 750 ng once daily</description>
        </group>
        <group group_id="B2">
          <title>SER120 1500 ng</title>
          <description>All participants received SER120 1500 ng once daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>All participants received Placebo once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="262"/>
            <count group_id="B2" value="260"/>
            <count group_id="B3" value="260"/>
            <count group_id="B4" value="782"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="8.8"/>
                    <measurement group_id="B2" value="66.1" spread="9.2"/>
                    <measurement group_id="B3" value="65.8" spread="9.0"/>
                    <measurement group_id="B4" value="66.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="220"/>
                    <measurement group_id="B4" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="249"/>
                    <measurement group_id="B4" value="734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment</title>
        <description>Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>SER120 750 ng</title>
            <description>All participants received SER120 750 ng once daily</description>
          </group>
          <group group_id="O2">
            <title>SER120 1500 ng</title>
            <description>All participants received SER120 1500 ng once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>All participants received Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment</title>
          <description>Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12</description>
          <population>intent to treat population</population>
          <units>nocturic episodes per night</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="260"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.06"/>
                    <measurement group_id="O2" value="-1.5" spread="0.06"/>
                    <measurement group_id="O3" value="-1.2" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With Equal of Greater Than 50% Reduction in Mean Nocturic Episodes</title>
        <description>Percent of participants with equal of greater than 50% reduction in mean nocturic episodes over the twelve week period</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>SER120 750 ng</title>
            <description>All participants received SER120 750 ng once daily</description>
          </group>
          <group group_id="O2">
            <title>SER120 1500 ng</title>
            <description>All participant received SER120 1500 ng once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>All participants received Placebo once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With Equal of Greater Than 50% Reduction in Mean Nocturic Episodes</title>
          <description>Percent of participants with equal of greater than 50% reduction in mean nocturic episodes over the twelve week period</description>
          <population>Intent to treat population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="260"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were collected from the Safety Population, i.e., any patient who had received one dose of study drug and reported an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>SER120 750 ng</title>
          <description>All participants received SER120 750 ng once daily</description>
        </group>
        <group group_id="E2">
          <title>SER120 1500 ng</title>
          <description>All participants received SER120 1500 ng once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>All participants received Placebo once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="267"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="266"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="264"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="266"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="264"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="266"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="264"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="267"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Serenity Pharmaceuticals</organization>
      <phone>8456396760 ext 17</phone>
      <email>sfein@serenitypharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

